And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. The agenda is rather modest, though, since we may spend part of the time dreaming about the day when we can resume close encounters of the previous kind. For now, we plan to hang with the short person, pretend that we are training the official mascot, and take a few naps. And what about you? This is a good time to check your supply of masks or, perhaps, plan your grocery shopping. You could binge-watch something on the telly or reach out, so to speak, to older folks who are cooped up. Well, whatever you do, chin up. Keep on the sunny side and stay safe. See you soon. …

A study found that hydroxychloroquine, a decades-old malaria drug touted by President Trump, did not appear to help hospitalized patients with Covid-19, CNBC says. The observational study looked at 1,376 consecutive patients who arrived at the emergency room with symptoms of coronavirus. Nearly 60%, or 811 of the patients, received the drug within 48 hours and were found, on average, to be more severely ill than those not given the drug. The findings did not find any potential benefit or harm from the drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Ed,

    If the STAT Team has not seen it, please get a copy of the Raymond James analysis of the NEJM Paper on HCQ. Spoiler Alert: If death becomes the only endpoint, not the more curious combined endpoint they used (death/intubation), the study may indeed be positive for HCQ. In the accompanying editorial the author states that HCQ is not a panacea for C-19. Neither is Remdesivir, or most types of chemotherapy for cancer. Panacea is not a reasonable or customary standard of efficacy. Regardless, we now have multiple large studies that seem to show using HCQ is safe. This study did not show any SAEs directly related to the drug. The MN Trial, which will read out shortly, has gone through three safety checks with not a single drug related event. The efficacy of HCQ is a very legitimate question that needs to be answered, however the safety issues have been way overblown by the media. Used in a 5 day pulse, under the supervision of an MD, this is a safe drug.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy